# EDGAR Filing Document

**Accession Number:** 0001130166
**File Stem:** 0001641172-25-017152
**Filing Date:** 2025-6
**Character Count:** 7926
**Document Hash:** fc90bb7c3b7f1f96f01524b0e5869c3a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-017152.hdr.sgml**: 20250630

**ACCESSION NUMBER**: 0001641172-25-017152

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250630

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250630

**DATE AS OF CHANGE**: 20250630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cyclacel Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001130166
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911766850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50626
- **FILM NUMBER:** 251092451

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-7330

**MAIL ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCYTE THERAPIES INC
- **DATE OF NAME CHANGE:** 20001218

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**June 30, 2025**

Date of Report (date of earliest event reported)

**Cyclacel Pharmaceuticals, Inc.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-50626** | **91-1707622** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification Number) |

---

**Level 10, Tower 11, Avenue 5, No. 8**

**Jalan Kerinchi, Kuala Lumpur, Malaysia 592000**

(Address of principal executive offices) (Zip code)

**(908) 517-7330**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | CYCC | The Nasdaq Capital Market |
| Preferred Stock, $0.001 par value | CYCCP | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

(a) The 2025 Annual Meeting of Cyclacel Pharmaceuticals, Inc. was held on June 30, 2025.

(b) The results of the matters submitted to a shareholder vote at the Annual Meeting were as follows:

1. <u>Election of Directors</u>: Our shareholders re-elected the following five (5) directors to each serve a three-year term expiring on the date of our 2028 annual meeting of shareholders or until his successor has been duly chosen and qualified.

1. A. Datuk Dr. Doris Wong

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** | **BROKER NON-VOTE** | **BROKER NON-VOTE** |
| **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** | **%** |
| 305050384 | 99.97% | 0 | 0% | 95025 | 0.03% | N/A | N/A |

---

1B. Kiu Cu Seng

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** | **BROKER NON-VOTE** | **BROKER NON-VOTE** |
| **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** | **%** |
| 305047294 | 99.97% | 0 | 0% | 98115 | 0.03% | N/A | N/A |

---

1. C. Kwang Fock Chong

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** | **BROKER NON-VOTE** | **BROKER NON-VOTE** |
| **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** | **%** |
| 305045327 | 99.97% | 0 | 0% | 100082 | 0.03% | N/A | N/A |

---

1. D. Dr. Satis Waran Nair Krishnan

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** | **BROKER NON-VOTE** | **BROKER NON-VOTE** |
| **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** | **%** |
| 305045506 | 99.97% | 0 | 0% | 99903 | 0.03% | N/A | N/A |

---

1. E. Inigo Angel Laurduraj

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** | **BROKER NON-VOTE** | **BROKER NON-VOTE** |
| **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** | **%** |
| 305045342 | 99.97% | 0 | 0% | 100067 | 0.03% | N/A | N/A |

---

2. <u>Approve a Proposed Amendment to the 2018 Equity Incentive Plan</u>. Our shareholders approved a proposed amendment to the Company's 2018 Equity Incentive Plan to increase the number of shares of Common Stock available for the grant of awards by 4,281,987.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** | **BROKER NON-VOTE** | **BROKER NON-VOTE** |
| **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** | **%** |
| 304957049 | 99.94% | 168539 | 0.05% | 19821 | 0.01% | N/A | N/A |

---

3. Approve by an Advisory Vote the Executive Compensation. Our shareholders approved by an advisory vote the compensation of our named executive officers and directors, as disclosed in this proxy statement.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** | **BROKER NON-VOTE** | **BROKER NON-VOTE** |
| **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** | **%** |
| 305004614 | 99.95% | 124873 | 0.04% | 15922 | 0.01% | N/A | N/A |

---

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 30, 2025 | **Cyclacel Pharmaceuticals, Inc.** | **Cyclacel Pharmaceuticals, Inc.** |
|  | By: | */s/ Datuk Dr. Doris Wong Sing Ee* |
|  | Name: | Datuk Dr. Doris Wong Sing Ee |
|  | Title: | Chief Executive Officer |

---